Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
Saved in:
| Title: | Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. |
|---|---|
| Authors: | van Wilpe S; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Simnica D; Department of Internal Medicine IV, Oncology/Haematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., Slootbeek P; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Ee T; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Pamidimarri Naga S; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Gorris MAJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands.; Oncode Institute, Utrecht, The Netherlands., van der Woude LL; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands.; Oncode Institute, Utrecht, The Netherlands., Sultan S; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Koornstra RHT; Department of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands., van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Kroeze LI; Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Simons M; Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., van Leenders GJLH; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands., Binder M; Department of Internal Medicine IV, Oncology/Haematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany., de Vries IJM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands. |
| Source: | Oncoimmunology [Oncoimmunology] 2022 Jul 01; Vol. 11 (1), pp. 2094133. Date of Electronic Publication: 2022 Jul 01 (Print Publication: 2022). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
